Upstream Bio Inc.

03/26/2026 | Press release | Distributed by Public on 03/26/2026 14:27

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on March 26, 2026

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

Upstream Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

38-4187694

(State or other jurisdiction of
incorporation or organization)

(I.R.S. employer
identification no.)

890 Winter Street, Suite 200

Waltham, MA

(Address of principal executive offices)

02451

(Zip Code)

Upstream Bio, Inc. 2024 Stock Option and Incentive Plan
(Full title of the plan)

E. Rand Sutherland, M.D.
Chief Executive Officer

Upstream Bio, Inc.
890 Winter Street, Suite 200

Waltham, MA 02451

(Name and address of agent for service)

(781) 208-2466

(Telephone number, including area code, of agent for service)

Copies to:
William D. Collins

Karin Yoo
Goodwin Procter LLP
100 Northern Avenue

Boston, Massachusetts 02210
(617) 570-1000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This Registration Statement on Form S-8 (this "Registration Statement") is being filed by Upstream Bio, Inc. (the "Registrant") with the U.S. Securities and Exchange Commission (the "Commission") to register 2,711,887 additional shares of the Registrant's common stock, par value $0.001 per share ("Common Stock"), available for issuance under the Registrant's 2024 Stock Option and Incentive Plan (the "Plan"), pursuant to the evergreen provisions of the Plan.

These additional shares are of the same class as other securities relating to the Plan for which the Registrant's Registration Statements on Form S-8 filed with the Commission on October 11, 2024 (File No. 333-282614) and March 12, 2025 (File No. 333-285729) (the "Earlier Registration Statements") are effective.

Pursuant to General Instruction E to Form S-8, the contents of the Earlier Registration Statements related to the Plan, except for "Item 8. Exhibits," are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Earlier Registration Statements are presented herein.

Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

EXHIBIT INDEX

Exhibit
No.

Description

4.1

Third Amended and Restated Certificate of Incorporation of Upstream Bio, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-42366) filed on October 15, 2024).

4.2

Second Amended and Restated Bylaws of Upstream Bio, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-42366) filed on October 15, 2024).

4.3

Amended and Restated Investors' Rights Agreement, among the Registrant and certain of its stockholders, dated June 6, 2023 (incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-282197) filed on September 18, 2024).

5.1*

23.1*

23.2*

24.1*

Power of Attorney (included on signature page).

99.1

Upstream Bio, Inc. 2024 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to Amendment No. 1 to the Registrant's Registration Statement on Form S-1 (File No. 333-282197) filed on October 7, 2024).

107*

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Massachusetts, on this 26th day of March, 2026.

UPSTREAM BIO, INC.

By:

/s/ E. Rand Sutherland

Name: E. Rand Sutherland, M.D.

Title: Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

Each individual whose signature appears below hereby constitutes and appoints each of E. Rand Sutherland, M.D. and Michael Paul Gray, M.B.A. as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

Name

Title

Date

/s/ E. Rand Sutherland

Chief Executive Officer and
Director

(Principal Executive Officer)

March 26, 2026

E. Rand Sutherland, M.D.

/s/ Michael Paul Gray

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

March 26, 2026

Michael Paul Gray, M.B.A.

/s/ Ronald C. Renaud, Jr.

Director and Chairman

March 26, 2026

Ronald C. Renaud, Jr., M.B.A.

/s/ Daniella Beckman

Director

March 26, 2026

Daniella Beckman

/s/ Erez Chimovits

Director

March 26, 2026

Erez Chimovits, M.B.A., M.Sc.

/s/ H. Edward Fleming, Jr.

Director

March 26, 2026

H. Edward Fleming, Jr., M.D.

/s/ Liam Ratcliffe

Director

March 26, 2026

Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.

/s/ Marcella Kuhlman Ruddy

Director

March 26, 2026

Marcella Kuhlman Ruddy, M.D., M.S.

Upstream Bio Inc. published this content on March 26, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 26, 2026 at 20:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]